Together, these data suggest that CA9 is an important therapeutic target in GBM and given its cell surface expression and limited expression in normal brain samples, immuno-therapeutic modalities targeting cells expressing CA9 have reduced risk of off-target toxicity in the brain. The gene discussed is CA9; the disease is glioblastoma.